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Summary.-Lymphocytes from 10 patients with breast carcinoma were seeded in
autologous serum, on autochthonous tumour cells and allogeneic tissue-cultured
breast tumour cell lines. In 4 patients, the anti-tumour cell cytotoxicity against at
least one of 3 breast tumour celllinesdiffered significantlyfromthat against autoch-
thonous tumour cells. Further study of these 4 individuals (using their previously
frozen lymphoid cells and sera) showed that these differences occurred because
serum which decreased (" blocked ") lymphocyte anti-tumour cytotoxicity when
applied to one tumour cell line, could either have no effect or potentiate it when
applied to another, without any consistent pattern vis-a-vis target-cell susceptibility
to these different humoral effects.
ALLOGEENEIC tumour cells which have
been maintained in tissue culture are
commonly used as target cells for in vitro
studies of humoral and cellular anti-
tumour immunity in man. It has been
claimed (Hellstrom et al., 1971), and
assumed by many, that the capacity of an
individual's lymphoid cells to inactivate
such tumour cells, and the degree to which
such inactivating effects can be modified
by humoral factors, is a fair reflection of
the way in which an individual can react
against malignant cells in his or her own
tumour. The principal purpose of the
present study was to determine whether
or not this was correct. This is obviously
a question of crucial importance, because
of the ever-increasing frequency with
which such tests are being performed in
attempts to establish in vitro correlates
for human tumour progression and re-
gression.
The results obtained show that dif-
ferences in the reactivities of individuals
with breast cancer against cells of their
own tumours and those derived from
allogeneic tissue-cultured breast tumour
cells are not infrequent, and they compel
one to conclude that the routine use of
target cells of allogeneic origin for in vitro
studies ofhuman anti-tumour immunity is
far from ideal.
MATERIALS AND METHODS
Patients.-Ten individuals (C17-26) with
primary breast carcinoma were studied.
Blood (25 ml clotted and 25 ml heparinized)
was obtained from each patient on the
morning of surgery and prior to the admini-
stration of any pre-operative medication.
Lymphoid cell8.-Previous publications
have described the solutions used in this
study (Jeejeebhoy, 1974) and the procedures
employed for separation of lymphoid cells on
a Ficoll-Hypaque gradient and their sub-
sequent freezing (Jeejeebhoy, 1975). When
lymphoid cells are separated from whole
blood in this manner there is enrichment
withrespecttomonocytes:thefinalsuspension
contains lymphocytes + 5-20% monocytes.
All lymphoid cells used were frozen and
stored in liquid N2 and only thawed immedi-
ately prior to seeding in the test plates.
There is little loss offunctional activity when
the procedures described by ourselves (Jee-H. F. JEEJEEBHOY
jeebhoy and Lawler, 1976) for the freezing
and thawing of tumour cells and lymphoid
cells are employed. In any case, it is only by
using effector cells which have been frozen
and stored in liquid N2 that one can repeat
and extend in vitro tests of anti-tumour
immunity as in this study.
Tumour cells.-Target cells for in vitro
studies were derived from 4 sources. Cell
lines 257742 and 306462 were derived from
the pleural effusions of 2 women who had
metastatic breast cancer in their pleural
cavities. The third tissue-culture genera-
tions of these 2 lines were frozen in aliquots.
Both tumour lines are capable of forming
colonies in soft agar, which suggests that they
contain malignant cells, though it can
certainly not be excluded that some of the
cells were of non-malignant and possibly
mesothelial origin. However, non-malignant
cells do not usually form colonies in soft agar
unless they are of haemopoietic origin. No
concerted attempt has been made to grow
these tumour cells inathymic nude mice. To
date, only a single animal has been inoculated
with cells from each of the 2 tumour lines,
and on neither occasion has a tumour
appeared.
Line BT20 cells were obtained from Dr
E. Lasfargues. This line was originally
derived from a human mammary adeno-
carcinoma, and forms progressively growing
tumours in athymic nude mice (Ozzello et al.,
1974). We froze it in aliquots at subculture
generation 282.
The fourth source was primary tumours.
Cell suspensions from these were prepared by
mechanical dissociation as previously de-
scribed (Jeejeebhoy, 1975). On some occa-
sions (C20-26) an attempt was made to
increase the number ofviable tumour cells by
utilizing only the interface which remained
when the initial tumour cell suspension was
washed and then centrifuged on Ficoll-
Hypaque (sp. gr. 1-078) as described by
Mavligit, Gutterman and Hersh (1973). If
the target cells which were to be used for in
vitro studies were not distinctly epithelial in
appearance, the experiment was not pro-
ceeded with. The difficulties involved in
preparing suitable cell suspensions from
primary breast tumours precluded the study
of many of the tumours obtained.
A vial ofeach ofLines 257742, BT20 and
306462 was thawed and placed in tissue
culture flasks on the day when a primary
tumour was received. On the day preceding
the performance of the in vitro assay, these
cells were treated in the same ways and
exposed to the same solutions as were the
cells of the primary tumours and they were
then seeded in the wells of the plastic plates
as described below.
Cytotoxicity tests.-A modification of a
previously described method (Takasugi and
Klein, 1970) was used for performance of in
vitro anti-tumour cytotoxicity studies.
Tumour cells were seeded in the wells of a
plastic plate (Falcon No. 3034). Those cells
which had not adhered to the plastic were
washed off after 24 h, and those which
remained were then exposed to any one or
more of the following: Group A-Tissue
culture medium containing 10% foetal calf
serum (FCS) previously heated at 56°C for
45 min; Group B-Lymphocytes in tissue
culture medium containing 10% FCS; Group
C-Undiluted serum from the donor of the
lymphoid cells; Group D-Lymphoid cells in
undiluted autologous serum. Eight wells
were seeded in each group. After incubation
at 37°C in 5% CO2 for 48 h, nonadherent cells
were washed off and the tumour cells which
remained attached to the bottoms ofthe wells
were then fixed, stained and counted.
Analysis of the results was based on the
assumption that cells which adhere to plastic
are viable, whereas those which initially do
but subsequently do not have been rendered
inviable. Hence, any statistically significant
reduction in the number of adherent tumour
cells with respect to an appropriate control
group was presumed to indicate some anti-
tumour-cell toxicity in that experimental
group.
Some justification needs to be provided at
this stage for seeding lymphoid cells on
tumour cells in undiluted autologous serum,
rather than some other arbitarily predeter-
mined serum dilution. It was done because
of one's possibly simplistic assumption that
this practice was more likely to identify
intravascular defence mechanisms inhibiting
the metastatic spread of cancer (if indeed
such mechanisms exist) because tumour cells
metastasize by the blood stream, in which
they are exposed to undiluted serum. Titra-
tion studies (Jeejeebhoy, 1975), using the
procedures described in this paper, have not
as yet demonstrated any prozone phenomena
but these do remain real possibilities. Nor
have these studies shown a sequence similar
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to that found in mouse systems, where
opposite effects occasionally result when sera
are diluted (Skurzak et al., 1972).
RESULTS
Controls
The question of what constitutes
adequate controls for studies of this type
is controversial. This controversy stems
from the fact that lymphoid cells from
apparently disease-free individuals are
often cytotoxic to tumour cells in vitro
(Takasugi, Mickey and Terasaki, 1973;
Jeejeebhoy, 1975; Berkelhammer et al.,
1975) and that sera from these same
individuals can often decrease (" block "
in the current terminology) or potentiate
these effects by agents which seem to be
immunologically specific for the tumour
cells (Jeejeebhoy, 1975). Hence, it is
impossible to exclude the possibility that
an apparently disease-free individual has
not already initiated an immune response
(cellular and/or humoral) to antigens
associated with the tumour cells being
used as target cells. It is, therefore,
extremely difficult to know who con-
stitutes a suitable, normal control subject
for studies of this type. Currently there
is no consensus on this matter.
I have attempted to resolve this
problem in the following ways:
(1) Lymphocyte anti-tumour cyto-
toxicity in medium containing 10% FCS is
expressed as the percentage change in the
mean numbers of adherent cells left in
Group B above with respect to Group A.
In this way, lymphocyte effects from
different individuals are expressed in
terms of a common baseline (the medium
control) and thus become comparable.
This avoids having to compare lympho-
cyte effects from individuals with breast
cancer with lymphocyte effects from
apparently disease-free individuals who
might nevertheless have already, for
someunknownreason, initiated animmune
response to antigens associated with
breast tumour cells.
(2) Percentage cytotoxicity in serum is
expressed as the percentage change in the
mean numbers of adherent cells in Group
D relative to Group C.
(3) To determine whether, and to what
extent, the serum of an individual is
capable of altering the anti-tumour cyto-
toxicity of her lymphoid cells, the per-
centage cytotoxicity of her lymphoid cells
in tissue culture medium is compared with
the percentage cytotoxicity in undiluted
autologous serum. A comparison of
lymphocyte effects in a milieu which does
not contain human serum with those in the
presence of human serum is not too
meaningful by itself. However, it is one
(and perhaps the only) way of comparing
serum effects from different individuals in
terms of whether the effect of serum is to
decrease (block) or increase (potentiate)
lymphocyte anti-tumour cytotoxicity. In
effect, everything is once again expressed
in terms of a common baseline, thus the
medium control and the necessity for
using " normal " serum for purposes of
comparison is avoided. For reasons al-
ready detailed, serum from apparently
disease-free individuals can never be pre-
sumed to be free of immunologically
specific substances directed against anti-
gens present in breast tumour cells.
The procedures described above are
devices to enable us to compare cellular
and humoral anti-tumour effects from
different individuals. Marginal impor-
tance should be attached to the absolute
values obtained on each occasion. Actu-
ally, the results obtained when the data
are analysed in the manner described are
not different from those which result ifone
follows the fairly common practice of
choosing suitable " normal " donors on
the basis of(a) the failure oftheirlymphoid
cells to alter the plating efficiency of
tumour cells as determined by the medium
control, and (b) the failure of their sera to
alter (by blocking or potentiation) the
anti-tumour cytotoxicity of lymphoid
cells from individuals with malignant
lesions ofhistological derivation similar to
that of the target cells.
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Comparison of effective lymphocyte anti-
tumour cytotoxicity (lymphocyte cytotoxicity
in undiluted autologous serum: ELAC)
againstautochthonous andallogeneic tumour
target cells
In this present study, the mean
numbers of adherent tumour cells which
remained in Groups A and C (the medium
and serum controls) were comparable
within an experiment (range of 50-70
cells/group between experiments). In
order to facilitate comprehension of the
tables, only percentage changes with
respect to these groups are indicated.
These percentages were always calculated
with respect to appropriate groups seeded
on the same plates.
Table I details results obtained in 10
TABLE I.-Cytotoxic Effects ofLymphocytes in Autologous Serum against Autochthonous
Breast Tumour Cells and Breast Tumour Cell Lines*
% Cytotoxicity relative to exposure of target cells
to serum alone, when lymphocytes in undiluted
autologous serum were seeded on:
Autochthonous
tumour cells
+10
-22
-42
-22
-45
-65
-34
-66
-82
- 2
- 4
-10
- 2
- 4
0
-25
-42
-64
-29
-45
-72
- 5
- 8
-32
-29
-25
-54
-29
-22
-74
Breast tumour cell lines
257742 306462 BT 20
- 2 N.D. -551
-27 N.D. -951
-52 N.D. -911
-17 N.D. -18
-52 N.D. -38
-58 N.D. -62
-32 N.D. -39
-75 N.D. -81
-92 N.D. -78
0 N.D. +10
-12 N.D. - 6
+ 7 N.D. +12
-32t - 9 -421
-64: -12 -811
-72: - 2 -961
-10 -29 -35
- 71t -52 -48
-14: -74 -82
-32 N.D. -35
-54 N.D. -60
-68 N.D. -75
0 - 2 -10
- 2 -12 - 1
-45 -29 -25
-28 -18 -19
-22 -12 -29
-66 -70 -48
-34 -70: - 71
-31 -95: -121
-68 -90 -141
* Separate Falcon microtest plates were seeded with either 250 cells/well of Lines 257742 and BT20.
375 cells/well of Line 306462, and 500, 1000 or 2000 cells/well of autochthonous tumour cells. The plates
were washed with tissue culture medium 24 h later, immediately prior to lymphocytes being seeded in the
wells. After washing, 50-70 tumour cells remained adherent to the bottoms of the wells in which Lines
257742, BT20 and 306462 had been seeded. Plating of autochthonous tumour cells was variable: the plate
chosen for the test was the one in which 50-70 tumour cells remained adherent after washing.
t Final ratio of mononuclear cells to tumour cells (assuming a mean of 60 tumour cells) was 1400: 1,
2800:1 or 5600:1.
Significant difference (P < 0-01 by a 2-tailed Mann-Whitney -U test) from % cytotoxicity when
autochthonous tumour cells were the target.
N.D. = Not done.
Lymphocyte
and serum
donor
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
Numbers of
lymphocytes
seeded on
tumour cellst
8,500
17,000
34,000
8,500
17,000
34,000
8,500
17,000
34,000
8,500
17,000
34,000
8,500
17,000
34,000
8,500
17,000
34,000
8,500
17,000
34,000
8,500
17,000
34,000
8,500
17,000
34,000
8,500
17,000
34,000
~ ~ ~ ~ -A
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separate experiments. Differing numbers
of lymphoid cells from each of C17-26
were seeded on target cells derived from
the autochthonous tumour and lines
257742, BT20 and sometimes 306462
also. Comparisons were made in auto-
logous serum because autochthonous tum-
our cells can never be presumed to be free
of host protein. On 4 occasions (C17,
C21, C22 amd C26) the ELAC levels
against cells of the autochthonous tumour
and those of at least one allogeneic breast
tumour cellline were significantly different.
Further studies were undertaken to
determine why ELAC against autochtho-
nous tumour cells and allogeneic tumour
cells were occasionally dissimilar; in
uarticular, to determine the relative con-
tributions made to these differences by
variations in lymphocyte anti-tumour cell
cytotoxicities against allogeneic target
cell lines, and modification of these
lymphocyte effects by humoral factors
contained in autologous serum. (Cyto-
toxic effects against autochthonous tum-
our cells cannot be analysed into the
contributions of cellular and humoral
factors because of the impossibility of
being certain that such tumour cells do
not already have immunologically specific
protein attached to their surfaces.) The
results obtained are detailed in Table II
and summarized in Table III. They
show: (1) target cell cytotoxicities of
lymphoid cells from any one individual
were approximately comparable against
each of the 3 allogeneic breast tumour cell
lines. (2) The differences noted in Table I
probably resulted, in the main, from the
different ways in which humoral factors
were capable of altering these lymphocyte
anti-tumour effects. Serum which de-
creased lymphocyte anti-tumour cyto-
toxicity when applied to one tumour line
could potentiate or leave it unaffected
when applied to another, without any
consistent pattern, vis-a-vis target cell
susceptibility to these different humoral
effects.
DISCUSSION
Effective lymphocyte anti-tumour-cell
cytotoxicities (lymphocyte cytotoxicities
in autologous serum) against 257742,
306462 and BT20 cells in the experiments
detailed inTables I and II were comparable
(differences of 20% and less are rarely
statistically significant in this type of in
vitro cytotoxicity assay). This suggests
that the results obtained represented real
phenomena and were not fortuitous and
unrepeatable observations. Within the
framework of this basic assumption there
are at least 3 questions which merit
consideration.
The first is whether the data obtained
representeffectsdirectedagainst malignant
TABLE III. Summary of all Statistically Significant Changes (P < 0-01) in Lymphocyte
Anti-tumour Cytotoxicity due to Sera, as Presented in Table II
Target cell line
No. lymphocytes f -
Serum donor seeded 257742
C17 8,5000 -
17,000
34,000 -
C21 8,500 0
17,000 +
34,000 +
C22 8,500 O
17,000 0
34,000 0
C26 8,500 0
17,000 O
34,000 O
+, Potentiation; -, Blocking; 0, No effect, N.D., Not done.
306462 BT 20
N.D. 0
N.D. O
N.D. O
+
4-
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breast epithelium, or some other cell type
or types. This a question of crucial
importance in the present context, but
one to which a categorical answer cannot
be given. One's feeling is that, for the
following reasons, the results do represent
effects directed against malignant breast
epithelium:
(1) No experiment which involved the
use of autochthonous tumour cells was
proceeded with, unless the target cells
were distinctly epithelial in appearance.
The reasons for feeling that these epithelial
cells were of malignant origin were 2-fold.
Firstly, because mechanical dissociation of
breast tumour fragments, as used in this
study, preferentially separates infiltrating
malignant epithelium. Occasionally the
fragments were sectioned after processing,
and areas of benign ductal epithelium,
lobular carcinoma in situ and tubular
carcinoma appeared intact. The pro-
cedure used seems to preferentially dis-
sociate cells infiltrating in Indian file or in
columns, and this perhaps accounts for
the low and often unusably low yield of
malignant cells. In this context, it should
also be mentioned that almost no cells of
any sort (epithelial or otherwise) are
obtained when breast lumps caused by
fibrocystic disease are subjected to pro-
cedures similar to those I have employed
for preparing cell suspensions from frag-
ments of malignant breast tumours.
Secondly, because it has been shown that
mechanical dissociation of tumour frag-
ments results in very little dissociation of
macrophages, in contrast with yields
following enzymatic digestion (Evans,
1973). Histological studies referred to
above have confirmed that this is so, and
that the exception also extends to fibro-
blasts.
(2) Lines 257742 and 306462 were used
at the third subculture generation. Cells
from both these lines form colonies in soft
agar, and line 257742 has been subcul-
tured to the 34th subculture generation,
at which stage it was inadvertently lost.
Repeated subculture was not tried with
line 306462. All these facts, taken to-
gether, suggest that at least some of the
cells in these 2 lines were of malignant
origin. BT20 is a cell line derived from a
breast adenocarcinoma (Lasfargues and
Ozzello, 1958) and it forms progressively
growing tumours in athymic nude mice
(Ozzello et al., 1974).
None of the above statements con-
clusively shows that the target cells were
derived from malignant breast epithe-
lium. Unfortunately, the present state of
scientific expertise in this area probably
precludes a more definite answer. For
what it is worth, the basic procedures
employed have the sanction of fairly
general usage, and the assumptions I have
made about the nature of the target cells
are not dissimilar to those made by most
workers in this field.
The second question is whether the
lymphocyte and serum effects seen were
nonspecific effects or represented immune
responses directed against antigenic
moieties present in breast tumour cells.
In a previous study (Jeejeebhoy, 1975),
lymphoidcellsfromdisease-freeindividuals
and individuals with breast cancer were
seeded on allogeneic breast tumour cells,
melanoma cells and fibroblasts in a single
experiment. Each of the lymphoid cell
preparations was cytotoxic to breast
tumour cells in the numbers used. Similar
numbers of lymphoid cells were also
occasionally cytotoxic to melanoma cells
and fibroblasts. However, the pattern of
the differences in the cytotoxic properties
of lymphoid cells from the different
individuals, vis-at-vis breast tumour cells,
was not similarly expressed against mela-
noma cells and fibroblasts, albeit in
different degree. In that study it was
alsofoundthathumoralanti-breasttumour
cell blocking and potentiating effects
could be absorbed out with breast tumour
cells but not with melanoma cells. All
these facts, taken together, suggest that
the effects seen when lymphoid cells and
sera from disease-free individuals or indi-
viduals with breast cancer are seeded on
breast tumour cells, are not nonspecific
effects but rather represent the con-
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sequences of immune responses directed
against antigens specific to breast tumour
cells.
The third question is how sera which
decreased lymphocyte anti-tumour cell
cytotoxicity when applied to one tumour
line, could potentiate or leave it unaltered
when applied to another. The sera used
could have contained immunologically
specific substances directed against histo-
compatibility antigens (because of pre-
vious pregnancies, blood transfusions or
recognized or unrecognized abortions) or
tumour-associated antigens, and for these
reasons any one or more of numerous
factors could have been responsible for the
differences noted: variations in the avidity
of tumour cells (Hellstrom and Hellstrom,
1974) orlymphoid cells(CurrieandBasham,
1972) for antibody or antigen-antibody
complexes, quantitative differences in the
amounts of free antibody, free antigen
and/or free antigen-antibody complexes,
etc. No consistent pattern of target-cell
susceptibility to humoral effects was noted.
It was therefore felt that further study
would probably not yield any clear-cut
answer, and was unlikely to be profitable.
In the context of this third question,
it is noteworthy that there have been
reports that lymphocyte effects against
different tumour-cell lines having the same
histological derivation, may not always
be comparable (Mukherji et al., 1975). The
fact that they were in the present study
may have been fortuitous, a consistent
pattern being maintained from experi-
ment to experiment because each of the
tumour lines had been frozen in aliquots
at a single point in time.
Finally, because of the problems in-
volved in utilizing target cells derived
from the autochthonous tumour, it is
pertinent to ask whether those derived
from allogeneic tumour-cell lines could
serve as adequate substitutes. Most
workers have assumed that they can
(Herberman and Oldham, 1975) and the
present results show that this is indeed
acceptable, if ELAC levels are determined
against not less than 3 lines, and the
results not accepted unless ELAC levels
against each of these 3 lines are compar-
able. These rather drastic caveats would
have certainly eliminated all the dis-
crepancies in the present study, but only
at the cost ofa large amount oflabour and
the failure to evaluate ELAC levels in a
significant proportion ofpatients. Clearly
then, the use of autochthonous tumour
cells for determination of ELAC levels
must remain the ideal.
A final note of pessimism is perhaps
appropriate. The vast literature per-
taining to in vitro studies of human anti-
tumour immunity is characterized by
results which are not regularly repro-
ducible, and by correlations between in
vitro data and clinical findings which are
regularly demonstrable by some, and
rarely by others (Herberman and Oldham,
1975). The present paper suggests one
cause for these discrepancies.
I am indebted to my wife for her
expert technical assistance, to Dr E.
Lasfargues for supplying line BT20 cells
and to the staff ofthe American Oncologic
Hospital without whose help and col-
laboration none of this work would have
been possible.
Part ofthis work was done while I was
a recipient of an Eleanor Roosevelt
Fellowship from the International Union
against Cancer. This work was supported
by U.S.P.H.S. grants CA-08856 and RR-
05539 from the National Institutes of
Health and by an appropriation from the
Commonwealth ofPennsylvania.
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